AGC Biologics and Gore have teamed up to improve downstream purification processes by using increased productivity of the Protein A step.
The collaboration between contract development manufacturing organization (CDMO) AGC and W.L Gore & Associates (Gore) includes the entirety of GORE Protein Capture Devices with protein A, which the firm says advances productivity in Protein A purification.
â€śThe goal of this collaboration is to combine the expertise of two industry leaders, enabling them to work together to optimize a long-standing challenge in the industry and better address customer drug development and manufacturing needs,â€ť Bill Barret, product specialist at Gore told BioProcess Insider.
The GORE family will run alongside AGCâ€™s monoclonal antibody (mAb) based CDMO services and the joint offering from both companies is available across multiple sites in AGCâ€™s network.
â€śTechnology is rapidly advancing pharmaceutical manufacturing today. It is an equalizer for streamlining downstream processes, reducing bottlenecks, and increasing productivity,â€ť Kasper MĂ¸ller, chief technology officer at AGC Biologics said.
â€śFor developers working with AGC Biologics, these types of technical differentiators are extremely important and play a significant role in getting products to clinical and commercial stages as quickly as possible.â€ť
According to the CDMO, by using GORE alongside its mAb-based services, biopharma firms can enable a full single-use downstream process. In turn, through increased productivity of the Protein A step, the companyâ€™s claim it can remove column bioburden from storage, decrease manufacturing footprint, and reduce costs for clinical and specific commercial production.
â€śProtein A is the first downstream step in the purification of antibody-based therapies. Gore has developed a high binding capacity, rapid cycle, low pressure drop membrane- based Protein A device that can be optimized for antibody-based therapeutics where high productivity is desired,â€ť said Barret.
Financial details of the deal have not been disclosed.